Cambium Bio Ltd Total Liabilities
Cambium Bio Ltd total liabilities. Based on the latest financial reports, Cambium Bio Ltd (CMB) has total liabilities worth AU$1.46 Million AUD (≈ $1.03 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Cambium Bio Ltd's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cambium Bio Ltd (1999–2025)
Total liabilities of Cambium Bio Ltd from 1999 to 2025. This chart illustrates how Cambium Bio Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore CMB long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Cambium Bio Ltd Competitors by Total Liabilities
The table below lists competitors of Cambium Bio Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DTI Group Ltd
AU:DTI
|
Australia | AU$5.64 Million |
|
Together Startup Network Ltd
TA:TGTR
|
Israel | ILA56.03 Million |
|
Fab-Form Industries Ltd.
V:FBF
|
Canada | CA$815.75K |
|
Diamond Citra Propertindo PT
JK:DADA
|
Indonesia | Rp276.22 Billion |
|
ADX Energy Ltd
AU:ADX
|
Australia | AU$28.98 Million |
|
Cohort
LSE:CHRT
|
UK | GBX232.81 Million |
|
Renoworks Software Inc
V:RW
|
Canada | CA$2.32 Million |
|
Bima Sakti Pertiwi Tbk PT
JK:PAMG
|
Indonesia | Rp163.87 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Cambium Bio Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cambium Bio Ltd total assets.
Liquidity & Leverage Metrics
Cambium Bio Ltd Total Liabilities Ratios Explained
Cambium Bio Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cambium Bio Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cambium Bio Ltd (1999–2025)
The table below shows the annual total liabilities of Cambium Bio Ltd from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.46 Million ≈ $1.03 Million |
-49.21% |
| 2024-06-30 | AU$2.87 Million ≈ $2.03 Million |
-35.22% |
| 2023-06-30 | AU$4.43 Million ≈ $3.14 Million |
+199.65% |
| 2022-06-30 | AU$1.48 Million ≈ $1.05 Million |
-66.09% |
| 2021-06-30 | AU$4.36 Million ≈ $3.09 Million |
+18.12% |
| 2020-06-30 | AU$3.70 Million ≈ $2.61 Million |
-58.61% |
| 2019-06-30 | AU$8.93 Million ≈ $6.32 Million |
+333.13% |
| 2018-06-30 | AU$2.06 Million ≈ $1.46 Million |
+93.57% |
| 2017-06-30 | AU$1.06 Million ≈ $753.49K |
-7.41% |
| 2016-06-30 | AU$1.15 Million ≈ $813.75K |
-12.02% |
| 2015-06-30 | AU$1.31 Million ≈ $924.88K |
-33.00% |
| 2014-06-30 | AU$1.95 Million ≈ $1.38 Million |
-71.69% |
| 2013-06-30 | AU$6.89 Million ≈ $4.88 Million |
+411.44% |
| 2012-06-30 | AU$1.35 Million ≈ $953.52K |
+45.97% |
| 2011-06-30 | AU$923.21K ≈ $653.23K |
+105.16% |
| 2010-06-30 | AU$450.00K ≈ $318.40K |
-95.34% |
| 2002-06-30 | AU$9.67 Million ≈ $6.84 Million |
-92.52% |
| 2001-06-30 | AU$129.20 Million ≈ $91.42 Million |
+0.72% |
| 2000-06-30 | AU$128.27 Million ≈ $90.76 Million |
-14.97% |
| 1999-06-30 | AU$150.86 Million ≈ $106.74 Million |
-- |
About Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing i… Read more